SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Alibaba Health Information Technology Limited (ALBBY) trades at a trailing P/E of 6.8. Trailing earnings yield is 14.68%. PEG 0.16 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (6.8); PEG ≤ 1.0 — Peter Lynch undervalued (0.16); earnings yield beats bond yields (14.68%).
- PEG Ratio 0.16 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 14.68% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 73/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ALBBY
Valuation Multiples
P/E (TTM)6.8
Forward P/EN/A
PEG Ratio0.16
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.32
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.78
Book Value / Share$0.00
Revenue / Share$37.93
FCF / Share$0.00
Yields & Fair Value
Earnings Yield14.68%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-0.47 |
$56.6M |
$-191.61M |
-338.6% |
| 2016 |
$-0.51 |
$475.08M |
$-207.63M |
-43.7% |
| 2017 |
$-0.23 |
$2.44B |
$-106.97M |
-4.4% |
| 2018 |
$-0.15 |
$5.1B |
$-81.95M |
-1.6% |
| 2019 |
$-0.01 |
$9.6B |
$-6.59M |
-0.1% |
| 2020 |
$0.52 |
$15.52B |
$348.59M |
2.2% |
| 2021 |
$-0.39 |
$20.58B |
$-265.56M |
-1.3% |
| 2022 |
$0.79 |
$26.76B |
$535.65M |
2% |
| 2023 |
$1.25 |
$27.03B |
$883.48M |
3.3% |
| 2025 |
$1.78 |
$30.6B |
$1.43B |
4.7% |
